Genocea to Present at Cantor Fitzgerald Healthcare Conference
September 20 2017 - 8:00AM
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical
company developing novel vaccines and immunotherapies targeting T
cell antigens, today announced that Chip Clark, president and
chief executive officer, will present a company overview at the
Cantor Fitzgerald Healthcare Conference on Wednesday, September 27,
2017 at 10:20 a.m. ET in New York City.
A live webcast of the presentations can be accessed by visiting
the "Events and Presentations" tab of the investor relations
section of the Genocea website at http://ir.genocea.com. A
replay of the webcasts will be archived for 30 days following the
presentation.
About Genocea Biosciences, Inc.Genocea is
harnessing the power of T cell immunity to develop life-changing
vaccines and immunotherapies. While traditional immunotherapy
discovery methods have largely used predictive methods to propose T
cell targets, or antigens, Genocea has successfully developed
ATLAS™, its proprietary technology platform, to identify clinically
relevant antigens of T cells based on actual human immune
responses. Genocea used ATLAS to identify the antigens in its lead
clinical candidate, GEN-003, an investigational immunotherapy to
treat genital herpes, and is currently using ATLAS in
immuno-oncology applications to develop neoantigen cancer vaccines
(with an IND filing expected by the end of 2017), general cancer
vaccines and a vaccine targeting cancers caused by Epstein-Barr
Virus. For more information, please visit www.genocea.com.
For media: Jennifer LaVinO:
617-715-6687jennifer.lavin@genocea.com
For investors: Jonathan PooleO: 617-876-8191
jonathan.poole@genocea.com
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Sep 2023 to Sep 2024